Frontiers in Immunology (Feb 2022)
Overexpression of FcεRI on Bone Marrow Mast Cells, but Not MRGPRX2, in Clonal Mast Cell Disorders With Wasp Venom Anaphylaxis
- Jessy Elst,
- Jessy Elst,
- Leander P. De Puysseleyr,
- Leander P. De Puysseleyr,
- Didier G. Ebo,
- Didier G. Ebo,
- Didier G. Ebo,
- Margaretha A. Faber,
- Margaretha A. Faber,
- Athina L. Van Gasse,
- Athina L. Van Gasse,
- Athina L. Van Gasse,
- Athina L. Van Gasse,
- Marie-Line M. van der Poorten,
- Marie-Line M. van der Poorten,
- Marie-Line M. van der Poorten,
- Marie-Line M. van der Poorten,
- Ine I. Decuyper,
- Ine I. Decuyper,
- Ine I. Decuyper,
- Ine I. Decuyper,
- Chris H. Bridts,
- Chris H. Bridts,
- Christel Mertens,
- Christel Mertens,
- Michel Van Houdt,
- Michel Van Houdt,
- Margo M. Hagendorens,
- Margo M. Hagendorens,
- Margo M. Hagendorens,
- Margo M. Hagendorens,
- Luc S. De Clerck,
- Luc S. De Clerck,
- Anke Verlinden,
- Katrien Vermeulen,
- Marie-Berthe Maes,
- Zwi N. Berneman,
- Peter Valent,
- Peter Valent,
- Vito Sabato,
- Vito Sabato,
- Vito Sabato
Affiliations
- Jessy Elst
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Jessy Elst
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Leander P. De Puysseleyr
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Leander P. De Puysseleyr
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Didier G. Ebo
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Didier G. Ebo
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Didier G. Ebo
- Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium
- Margaretha A. Faber
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Margaretha A. Faber
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Athina L. Van Gasse
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Athina L. Van Gasse
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Athina L. Van Gasse
- Department of Paediatrics and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Athina L. Van Gasse
- Paediatrics, Antwerp University Hospital, Antwerp, Belgium
- Marie-Line M. van der Poorten
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Marie-Line M. van der Poorten
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Marie-Line M. van der Poorten
- Department of Paediatrics and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Marie-Line M. van der Poorten
- Paediatrics, Antwerp University Hospital, Antwerp, Belgium
- Ine I. Decuyper
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Ine I. Decuyper
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Ine I. Decuyper
- Department of Paediatrics and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Ine I. Decuyper
- Paediatrics, Antwerp University Hospital, Antwerp, Belgium
- Chris H. Bridts
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Chris H. Bridts
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Christel Mertens
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Christel Mertens
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Michel Van Houdt
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Michel Van Houdt
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Margo M. Hagendorens
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Margo M. Hagendorens
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Margo M. Hagendorens
- Department of Paediatrics and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Margo M. Hagendorens
- Paediatrics, Antwerp University Hospital, Antwerp, Belgium
- Luc S. De Clerck
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Luc S. De Clerck
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Anke Verlinden
- Department of Haematology, Antwerp University Hospital, Antwerp, Belgium
- Katrien Vermeulen
- Department of Clinical Biology, Antwerp University Hospital, Antwerp, Belgium
- Marie-Berthe Maes
- Department of Clinical Biology, Antwerp University Hospital, Antwerp, Belgium
- Zwi N. Berneman
- Department of Haematology, Antwerp University Hospital, Antwerp, Belgium
- Peter Valent
- Division of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
- Peter Valent
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
- Vito Sabato
- Department of Immunology, Allergology, Rheumatology and the Infla-Med Centre of Excellence, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
- Vito Sabato
- Immunology, Allergology, Rheumatology, Antwerp University Hospital, Antwerp, Belgium
- Vito Sabato
- Department of Immunology and Allergology, AZ Jan Palfijn Gent, Ghent, Belgium
- DOI
- https://doi.org/10.3389/fimmu.2022.835618
- Journal volume & issue
-
Vol. 13
Abstract
BackgroundUncertainties remain about the molecular mechanisms governing clonal mast cell disorders (CMCD) and anaphylaxis.ObjectiveThis study aims at comparing the burden, phenotype and behavior of mast cells (MCs) and basophils in patients with CMCD with wasp venom anaphylaxis (CMCD/WVA+), CMCD patients without anaphylaxis (CMCD/ANA-), patients with an elevated baseline serum tryptase (EBST), patients with wasp venom anaphylaxis without CMCD (WVA+) and patients with a non-mast cell haematological pathology (NMHP).MethodsThis study included 20 patients with CMCD/WVA+, 24 with CMCD/ANA-, 19 with WVA+, 6 with EBST and 5 with NMHP. We immunophenotyped MCs and basophils and compared baseline serum tryptase (bST) and both total and venom specific IgE in the different groups. For basophil studies, 13 healthy controls were also included.ResultsHigher levels of bST were found in CMCD patients with wasp venom anaphylaxis, CMCD patients without anaphylaxis and EBST patients. Total IgE levels were highest in patients with wasp venom anaphylaxis with and without CMCD. Bone marrow MCs of patients with CMCD showed lower CD117 expression and higher expression of CD45, CD203c, CD63, CD300a and FcεRI. Within the CMCD population, patients with wasp venom anaphylaxis showed a higher expression of FcεRI as compared to patients without anaphylaxis. Expression of MRGPRX2 on MCs did not differ between the study populations. Basophils are phenotypically and functionally comparable between the different patient populations.ConclusionPatients with CMCD show an elevated burden of aberrant activated MCs with a significant overexpression of FcεRI in patients with a wasp venom anaphylaxis.
Keywords
